Nephros Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 7% to $5.2M in Q1, driven by programmatic and service growth, while gross margin declined to 57% due to tariffs and mix. Strategic focus is on expanding into new verticals, leveraging technology and education, and building recurring revenue through services. Margin recovery is expected as tariffs expire.
-
Record Q1 revenue of $5.2M was driven by 23% programmatic growth, offsetting lower emergency response sales. Gross margin fell to 57% due to tariffs, currency, and product mix, but margin improvement is expected as lower tariffs take effect.
Fiscal Year 2025
-
Revenue grew 33% to $18.8M in 2025 with net income of $1.2M, driven by programmatic sales and service expansion. Gross margin held at 62% for the year despite tariff pressures, and the company remains debt-free with $5.4M in cash.
-
Q3 2025 revenue rose 35% year-over-year to $4.8M, marking the fifth consecutive profitable quarter, with strong growth in programmatic and service revenue. New PFAS solutions and expansion into non-hospital verticals are expected to drive future growth.
-
Q2 2025 saw 36% revenue growth and the third straight profitable quarter, driven by strong programmatic sales, new customer additions, and improved gross margins. Expansion into new verticals and product innovations are fueling sustainable growth.
Fiscal Year 2024
-
Q4 2024 saw 19% sales growth and a return to profitability, driven by core business expansion and new product launches. Gross margins improved, and the company ended the year debt-free with a strong cash position, setting the stage for growth in 2025.
-
Q3 2024 marked the first profitable quarter, with net income of $0.2M and gross margin rising to 61%. Revenue was $3.5M, up 8% sequentially but down 6% year-over-year, as cost controls and operational improvements offset programmatic declines.
-
Q2 2024 saw strong growth in core programmatic business and record customer sites, but total revenue declined 8% due to a sharp drop in emergency response sales. Gross margins remained robust, and net loss improved significantly year-over-year.